You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東瑞製藥(02348.HK)向康方生物(09926.HK)悉售創新藥物產品研發合資35%股權
東瑞製藥(02348.HK)公佈,其全資附屬東瑞生物向康方生物(09926.HK)的全資附屬中山康方,悉售東瑞生物於康融東方的35%股權,購買價爲2.67億元人民幣(下同)。該協議亦要求康融東方償還無抵押貸款及截至昨日(8日)的應計利息。於昨日,上述無抵押貸款的未償還本金總額爲1.16億元。因此,東瑞生物根據該協議有權收取合共3.9億元。 東瑞製藥估計出售事項將確認稅前收益淨額約2.67億至2.85億元,出售所得資源將用於研發項目以及製造及銷售活動。 康融東方爲康方生物與東瑞製藥於2017年成立的合營企業,主要從事創新藥物產品研發,包括已於2023年6月提交新藥上市申請的用於治療代謝類疾病的一類新藥伊努西單抗(AK102,PCSK9單抗)及正處於II期臨牀試驗的用於晚期實體腫瘤治療的一類新藥普絡西單抗(AK109,VEGFR-2單抗)。 康方生物認爲,將康融東方創新藥物產品全面融入公司旗下腫瘤和非腫瘤產品管線,將有利於該兩款產品後續臨牀開發及商業計劃的整體高效運作。公司將從未來商業化發展、產能利用等方面進行整體規劃與安排,充分發揮在研發、生產和商業化的成本與協同效應的優勢。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account